gavreto
(Pralsetinib)Rigel Pharmaceuticals, Inc.
Usage: GAVRETO is indicated for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and for adult and pediatric patients (12+ years) with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy, particularly if radioactive iodine-refractory.